Ckd Bio - Asset Resilience Ratio
Ckd Bio (063160) has an Asset Resilience Ratio of 0.02% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Ckd Bio's Asset Resilience Ratio has changed over time. Check Ckd Bio (063160) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Ckd Bio's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ckd Bio (063160) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩70.26 Million | 0.02% |
| Total Liquid Assets | ₩70.26 Million | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Ckd Bio maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ckd Bio Industry Peers by Asset Resilience Ratio
Compare Ckd Bio's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 15.57% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Ckd Bio (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Ckd Bio.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.02% | ₩70.20 Million ≈ $47.57K |
₩299.87 Billion ≈ $203.22 Million |
0.00pp |
| 2024-12-31 | 0.02% | ₩69.92 Million ≈ $47.38K |
₩284.49 Billion ≈ $192.80 Million |
+0.00pp |
| 2023-12-31 | 0.02% | ₩69.55 Million ≈ $47.13K |
₩293.79 Billion ≈ $199.09 Million |
-2.56pp |
| 2022-12-31 | 2.58% | ₩8.07 Billion ≈ $5.47 Million |
₩312.59 Billion ≈ $211.84 Million |
+2.56pp |
| 2021-12-31 | 0.02% | ₩69.03 Million ≈ $46.78K |
₩298.54 Billion ≈ $202.32 Million |
0.00pp |
| 2020-12-31 | 0.02% | ₩69.99 Million ≈ $47.43K |
₩283.46 Billion ≈ $192.10 Million |
-0.01pp |
| 2019-12-31 | 0.03% | ₩71.58 Million ≈ $48.51K |
₩233.35 Billion ≈ $158.14 Million |
-2.60pp |
| 2018-12-31 | 2.63% | ₩4.86 Billion ≈ $3.29 Million |
₩184.52 Billion ≈ $125.05 Million |
-0.70pp |
| 2017-12-31 | 3.34% | ₩5.99 Billion ≈ $4.06 Million |
₩179.48 Billion ≈ $121.63 Million |
+2.26pp |
| 2016-12-31 | 1.07% | ₩1.94 Billion ≈ $1.32 Million |
₩180.91 Billion ≈ $122.60 Million |
+0.86pp |
| 2014-12-31 | 0.22% | ₩360.00 Million ≈ $243.97K |
₩165.07 Billion ≈ $111.86 Million |
-0.94pp |
| 2011-12-31 | 1.16% | ₩2.30 Billion ≈ $1.56 Million |
₩198.29 Billion ≈ $134.38 Million |
-- |
About Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also e… Read more